Prestige Consumer Healthcare Inc. Revenue & Financials

Prestige Consumer Healthcare closed the fiscal year 2024 with total net sales of $1.13 billion, representing a solid 4.2% increase from the $1.08 billion reported in FY2023, driven by organic growth in key categories and successful integration of recent minor acquisitions. The company’s gross profit margin expanded to 58.5%, a testament to effective pricing strategies, favorable product mix shifts toward higher-margin items, and ongoing supply chain optimizations that mitigated inflationary pressures on raw materials and freight costs. Operating income remained robust, with operating margins hovering around 32.5%, reflecting the company’s disciplined control over selling, general, and administrative expenses despite increased investments in digital marketing and e-commerce infrastructure. Net income for the year translated to an earnings per share (EPS) of $3.85, reflecting a highly profitable business model that generates substantial free cash flow even during periods of moderate revenue growth. The company’s balance sheet remains strong, with a net debt-to-EBITDA ratio comfortably within its target range, allowing for continued flexibility in pursuing accretive acquisitions and returning capital to shareholders through share repurchases and dividends. Prestige’s return on invested capital (ROIC) consistently exceeds 15%, demonstrating the efficiency of its asset-light model and its ability to generate high returns on incremental capital deployed into brand building and market expansion. The financial narrative of Prestige is one of consistent, predictable performance, characterized by steady top-line growth, margin expansion, and exceptional cash flow generation, making it an attractive investment for those seeking exposure to the defensive consumer healthcare sector with a focus on capital efficiency and shareholder returns.